Marex Group’s Pasithea Therapeutics Warrants KTTAW Stock Holding History
Bought
Maintained
Sold
Marex Group's KTTAW Position: Q3 2026 in Review
Marex Group sold out of Pasithea Therapeutics Warrants (KTTAW) in Q3 2026, closing a stake of 25,000 shares — an estimated $223 sold.
Marex Group first reported a position in KTTAW in Q4 2023 and held it in 11 quarters. The position peaked at $925 in Q4 2024. 0 funds tracked by Wall St. Rank hold KTTAW as of Q3 2026.
- Marex Group reported no remaining Pasithea Therapeutics Warrants position as of Q3 2026 after selling out during the quarter.
- Marex Group sold 25,000 Pasithea Therapeutics Warrants shares in Q3 2026, an estimated $223.
- Marex Group first reported a position in Pasithea Therapeutics Warrants in Q4 2023 and held it in 11 quarters.
- Marex Group's Pasithea Therapeutics Warrants position peaked at $925 in Q4 2024.
- 0 funds tracked by Wall St. Rank held Pasithea Therapeutics Warrants as of Q3 2026.
Based on Marex Group's 13F filing for Q3 2026, filed 16 Nov 2026.